|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-11-26
|
|
pubmed:abstractText |
The role of nephron-sparing surgery (NSS) showed promise in patients with metastatic renal cell carcinoma (MRCC). The disease-specific survival of patients with MRCC was compared according to the type of surgery, NSS (N=45) versus radical nephrectomy (RN) (N=732), in unmatched and matched analyses.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright (c) 2007 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
110
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2428-33
|
|
pubmed:meshHeading |
pubmed-meshheading:17941033-Adult,
pubmed-meshheading:17941033-Aged,
pubmed-meshheading:17941033-Aged, 80 and over,
pubmed-meshheading:17941033-Carcinoma, Renal Cell,
pubmed-meshheading:17941033-Disease-Free Survival,
pubmed-meshheading:17941033-Female,
pubmed-meshheading:17941033-Humans,
pubmed-meshheading:17941033-Kidney Neoplasms,
pubmed-meshheading:17941033-Male,
pubmed-meshheading:17941033-Middle Aged,
pubmed-meshheading:17941033-Neoplasm Metastasis,
pubmed-meshheading:17941033-Nephrectomy,
pubmed-meshheading:17941033-Survival Analysis,
pubmed-meshheading:17941033-Survival Rate,
pubmed-meshheading:17941033-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma.
|
|
pubmed:affiliation |
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
